“The ability to offer additional treatment options to heart failure patients whose disease has progressed to the point that optimal medical therapy is no longer able to manage the symptoms is imperative,” said Jason R. Foerst, MD, medical director of the Carilion Clinic Structural Heart and Valve Program and assistant professor of medicine at Virginia Tech Carilion School of Medicine, whose team enrolled the first patient in the CORCINCH-HF Study. “My team and I are excited to be a part of the CORCINCH-HF Study and look forward to working with Ancora Heart to fulfill our role in this very important clinical trial.”
Carilion Clinic Structural Heart and Valve Program team enrolls first patient in Ancora Heart CORCINCH-HF Study
